Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently
needed on a global basis because treatment failure is an increasing problem. Drug …

Leishmaniasis is caused by an intracellular parasite transmitted to humans by the bite of a
sand fly. It is endemic in Asia, Africa, the Americas, and the Mediterranean region …

Governed by parasite and host factors and immunoinflammatory responses, the clinical
spectrum of leishmaniasis encompasses subclinical (inapparent), localised (skin lesions) …

Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …

Introduction: Leishmaniasis is a vector-borne neglected tropical disease which manifests as
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous …

The control of Leishmania infection relies primarily on chemotherapy till date. Resistance to
pentavalent antimonials, which have been the recommended drugs to treat cutaneous and …

Pentavalent antimonials are first-line drugs for the treatment of the cutaneous form of
American tegumentary leishmaniasis. Second-line drugs include amphotericin B and …

Leishmaniases are diseases that are caused by protozoa of the genus Leishmania, which
are prevalent in tropical and subtropical areas, and which consist of both visceral and …

Background Cutaneous leishmaniasis (CL) is treated with parenteral drugs for decades with
decreasing rate cures. Miltefosine is an oral medication with anti-leishmania activity and …

The causative species of cutaneous leishmaniasis determines the clinical features and
courses, and treatments. Intralesional or systemic antimonials are the gold standard for the …